Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

139 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

NCT00197483

Schizophrenia Negative Symptoms Cognitive Impairments

SUSPENDED

Self-Management Therapy for Youth With Schizophrenia

NCT00000387

Schizophrenia

COMPLETED PHASE3

Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia

NCT02248987

Schizophrenia

COMPLETED

Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

NCT00833547

Schizophrenia

COMPLETED NA

Cognition, Functioning and Quality of Life

NCT00182442

Schizophrenia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We attempted to reduce the dose of antipsychotics to ≤1000-mg chlorpromazine eq./day. The dose was gradually reduced at a rate of ≤50-mg chlorpromazine eq./week, and the reduction was discontinued if the subjects relapsed. The differences in baseline cognitive function were analyzed between the patients with no relapse and relapse groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Relapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

reduction group

dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week

Group Type EXPERIMENTAL

reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* inpatients with a diagnosis of schizophrenia, and
* those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg chlorpromazine eq./day.

Exclusion Criteria

* mental retardation,
* substance abuse or dependence,
* a history of major head trauma,
* serious medical or neurological disorders, or
* depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No